Induction of natural killer suppressive factor in murine peritoneal cavity by intraperitoneal bolus administration of high-dose cisplatin

International Journal of Clinical Oncology

Volumn 5, Issue 1, 2000, Pages 48-53

  Ishikawa, Koichi ^a   Shimoda, Katsuhiro ^a   Shiraishi, Norio ^a   Adachi, Yosuke ^a   Kitano, Seigo ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Cisplatin; Intraperitoneal chemotherapy; Natural killer cell activity; Natural killer suppressive factor; Peritoneal cavity

Indexed keywords

CISPLATIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERITONEAL EXUDATE CELL; PERITONEUM METASTASIS; PRIORITY JOURNAL; STOMACH CARCINOMA;

EID: 0034125520     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470050009     Document Type: Article

References (26)

1. Maehara Y, Moriguchi S, Kakeji Y, et al. (1991) Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery 110:820-823
2. Averbach AM, Jacquet P (1996) Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 83:726-733
3. Leichman L, Berry BT (1991) Cisplatin therapy for adenocarcinoma of the stomach. Semin Oncol 18:25-33
4. Sautner T, Hofbauer F, Depisch D, et al. (1994) Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 12:970-974
5. Kurihara N, Kubota T, Hoshiya Y, et al. (1996) Antitumour activity of cis-diamminedichloroplatinum (II) against human tumour xenografts depends on its area under the curve in nude mice. J Surg Oncol 61:138-142
6. Brittenden J, Heys SD, Ross J, et al. (1996) Natural killer cells and cancer. Cancer 77:1226-1243
7. Kurosawa S, Harada M, Matsuzaki G, et al. (1995) Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes. Immunology 85:338-346
8. Baxevanis CN, Reclos GJ, Gritzapis AD, et al. (1993) Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 72:491-501
9. 2. Scand J Immunol 37:71-76
10. 2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J Leukoc Biol 44:474-484
11. Braun DP, Ahn MC, Harris JE, et al. (1993) Sensitivity of tumoricidal function in macrophages from different anatomical sites of cancer patients to modulation of arachidonic acid metabolism. Cancer Res 53:3362-3368
12. Pruimboom WM, Bac DJ, van DA, et al. (1995) Levels of soluble intercellular adhesion molecule 1, eicosanoids and cytokines in ascites of patients with liver cirrhosis, peritoneal cancer and spontaneous bacterial peritonitis. Int J Immunopharmacol 17:375-384
13. Mihich E, Ehrke M (1991) Immunomodulation by anticancer drugs. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer. Lippincott, Philadelphia, pp 776-786
14. Shimoda K, Saito T, Kobayashi M, et al. (1992) Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432. Biotherapy 5:63-69
15. Kluchareva TE, Matveeva VA, Kushlinsky NE (1992) In vitro bioassay for type E prostaglandins based on their NK immunodepressing activity. Immunol Lett 33:239-245
16. Scodras JM, Parhar RS, Kennedy TG, et al. (1990) Prostaglandinmediated inactivation of natural killer cells in the murine decidua. Cell Immunol 127:352-367
17. Bagasra O, Currao L, DeSouza LR, et al. (1985) Immune response of mice exposed to cis-diamminedichloroplatinum. Cancer Immunol Immunother 19:142-147
18. Brunda MJ, Taramelli D, Holden HT, et al. (1983) Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice. J Immunol 130:1974-1979
19. Austyn JM, Gordon S (1981) F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 11:805-815
20. Nelson JA, Parhar RS, Scodras JM, et al. (1990) Characterization of macrophage subsets regulating murine natural killer cell activity. J Leukoc Biol 48:382-393
21. Singh RK, Sodhi A, Singh SM (1991) Production of interleukin-1 and tumor necrosis factor by cisplatin-treated murine peritoneal macrophages. Nat Immun Cell Growth Regul 10:105-116
22. Burke GA, Keenan AK (1993) Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 α/ β, tumor necrosis factor-α and interferon-γ. Immunopharmacology 25:1-9
23. Topley N, Petersen MM, Mackenzie R, et al. (1994) Human peritoneal mesothelial cell prostaglandin synthesis: induction of cyclooxygenase mRNA by peritoneal macrophage-derived cytokines. Kidney Int 46:900-909
24. Offner FA, Feichtinger H, Stadimann S, et al. (1996) Transforming growth factor-β synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am J Pathol 148:1679-1688
25. Parhar RS, Lala PK (1985) Changes in the host natural killer cell population in mice during tumor development. 2. The mechanism of suppression of NK activity. Cell Immunol 93:265-279
26. Lala PK, Saarloos MN (1994) Prostaglandins and the host immune system: application of prostaglandin inhibitors for cancer immunotherapy. In: Harris JE, Braun DP, Anderson KM (eds) Prostaglandin inhibitors in tumor immunology and immunotherapy. CRC Press, Boca Raton, pp 187-227